Abstract:Background: Tripartite motif-containing (TRIM) 21 has been implicated in the pathogenesis of several types of autoimmune diseases. Objective: We sought to elucidate TRIM21 expression in patients with inflammatory bowel diseases (IBDs) and its role in regulating intestinal mucosal inflammation. Methods: TRIM21 expression was analyzed in the inflamed mucosa of patients with IBDs by means of quantitative RT-PCR and immunohistochemistry. Peripheral blood CD4(+) T cells were transfected with lentivirus-expressing TRIM21 (LV-TRIM21) or LV-sh-TRIM21, and cytokine expression was determined by using quantitative RT-PCR and ELISA. TRIM21(-/-) mice were generated, and trinitrobenzene sulfonic acid- and CD45RB(high) CD4(+) T cell-induced colitis models were established to determine its role in induction of intestinal inflammation. Results: TRIM21 was expressed predominantly in CD4(+) T cells and decreased markedly in the inflamed mucosa of patients with IBDs compared with healthy control subjects. Ectopic expression of TRIM21 inhibited IBD CD4(+) T cells to differentiate into T(H)1 and T(H)17 cells, whereas downregulation of TRIM21 had the opposite effects. TRIM21(-/-) mice had more severe colitis after administration of trinitrobenzene sulfonic acid compared with wild-type mice, which was characterized by increased expression of IFN-gamma, TNF-alpha, and IL-17A in the colon. TRIM21(-/-) CD45RB(high) CD4(+) T cells reconstituted into recombination-activating gene (Rag1)(-/-) mice induced more severe colitis than in wild-type control mice. Mechanistically, interferon regulatory factor 3 was identified as a functional downstream target of TRIM21 in that silencing of interferon regulatory factor 3 suppressed TRIM21(-/-) CD4(+) T-cell differentiation into T(H)1 and T(H)17 cells. Conclusions: TRIM21 plays a protective role in mucosal inflammation through inhibiting T(H)1 and T(H)17 cell differentiation. Thus TRIM21 might serve as a potential therapeutic target for the treatment of IBDs.

TRIM Proteins in Inflammation: from Expression to Emerging Regulatory Mechanisms

To TRIM the Immunity: From Innate to Adaptive Immunity

Tripartite Motif-Containing (TRIM) 21 Negatively Regulates Intestinal Mucosal Inflammation Through Inhibiting TH1/TH17 Cell Differentiation in Patients with Inflammatory Bowel Diseases.

Multifaceted Roles of TRIM38 in Innate Immune and Inflammatory Responses

InTRIMsic immunity: Positive and negative regulation of immune signaling by tripartite motif proteins

TRIM 30 a negatively regulates TLR-mediated NF-j B activation by targeting TAB 2 and TAB 3 for degradation

Tripartite-motif proteins and innate immune regulation

Tripartite Motif Family Proteins in Inflammatory Bowel Disease: Mechanisms and Potential for Interventions

Trim38 Negatively Regulates Tlr3/4-Mediated Innate Immune and Inflammatory Responses by Two Sequential and Distinct Mechanisms

Multifaceted role of TRIM21 in inflammation

Trim30 Alpha Negatively Regulates Tlr-Mediated Nf-Kappa B Activation By Targeting Tab2 And Tab3 For Degradation

TRIM30α negatively regulates TLR-mediated NF-κB activation by targeting TAB2 and TAB3 for degradation

TRIM38 Inhibits TNFα- and IL-1β–triggered NF-κB Activation by Mediating Lysosome-Dependent Degradation of TAB2/3

The Multifunction of TRIM26: From Immune Regulation to Oncology

TRIM50 Promotes NLRP3 Inflammasome Activation by Directly Inducing NLRP3 Oligomerization

The E3 Ubiquitin Ligase TRIM65 Negatively Regulates Inflammasome Activation Through Promoting Ubiquitination of NLRP3

Regulation of Tripartite Motif-Containing Proteins on Immune Response and Viral Evasion

TRIM Proteins in Fibrosis.

TRIM26 Positively Regulates the Inflammatory Immune Response Through K11-linked Ubiquitination of TAB1

A Interacting Model: How TRIM21 Orchestrates with Proteins in Intracellular Immunity

Multipronged regulation of autophagy and apoptosis: emerging role of TRIM proteins